The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

  • See Evidence submitted by expert panel for details.

Variant: NM_007123.5(USH2A):c.4338_4339delCT (p.Cys1447Glnfs)

CA252228

2353 (ClinVar)

Gene: USH2A
Condition: Usher syndrome
Inheritance Mode: Autosomal recessive inheritance
UUID: 5fc296e5-bbfb-4876-ace3-0e1618efc366
Approved on: 2018-09-25
Published on: 2019-07-17

HGVS expressions

NM_007123.5:c.4338_4339delCT
NM_007123.5(USH2A):c.4338_4339delCT (p.Cys1447Glnfs)
NC_000001.11:g.216190284_216190285del
CM000663.2:g.216190284_216190285del
NC_000001.10:g.216363626_216363627del
CM000663.1:g.216363626_216363627del
NC_000001.9:g.214430249_214430250del
NG_009497.1:g.238116_238117del
NM_007123.5:c.4338_4339del
NM_206933.2:c.4338_4339del
NM_206933.3:c.4338_4339del
ENST00000307340.7:c.4338_4339del
ENST00000366942.3:c.4338_4339del
More

Pathogenic

The Expert Panel has overridden the computationally generated classification - "Uncertain Significance - Insufficient Evidence"
Met criteria codes 5
PP1_Moderate PVS1 PM2 PP4 PM3_Very Strong
Not Met criteria codes 18
BP7 BP5 BP4 BP3 BP2 PM6 PM5 PM4 PM1 PS1 PS3 PS4 PS2 BA1 PP3 BS2 BS1 BS4

Evidence Links 7

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
Hearing Loss VCEP
The allele frequency of the p.Cys1447GlnfsX29 variant in the USH2A gene is 0.0009% (1/111250) of European (Non-Finnish) chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org), which is a low enough frequency to award PM2 based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive hearing loss (PM2). The p.Cys1447GlnfsX29 variant is predicted to cause a premature stop codon in biologically-relevant-exon 20 of 72 that leads to an absent protein in a gene in which loss-of-function is an established mechanism (PVS1). This variant has been detected as compound heterozygous with p.Cys759Phe or p.Glu767SerfsX21 in six Usher syndrome probands, and as homozygous in eight Usher syndrome probands (PM3_VeryStrong; PMID: 9624053, 15325563, 18641288, 18665195, 20440071). The p.Cys1447GlnfsX29 variant in USH2A has been reported to segregate with hearing loss in at least 2 family members (PP1_Moderate; PMID: 20440071, 9624053). At least one patient with a variant in this gene displayed features of mild to severe hearing loss and retinitis pigmentosa (PP4; PMID: 9624053, 15325563, 18641288, 18665195, 20440071). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Usher syndrome based on the ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PM2, PVS1, PM3_VeryStrong, PP1_Moderate, PP4.
Met criteria codes
PP1_Moderate
There are a 2 families that both have 2 affected and 2 unaffected individuals documented which counts as 2 affected segregations and 4 unaffected segregations total across the two families which allows the application of PP1_S (LOD = 1.7). RS: I'm not sure I would include the Eudy family, because it is unclear whether everyone was sequenced in the family. Therefore, PP1_Moderate would be applied (LOD:1.45)

PVS1
This variant causes a stop codon in the last exon of the shorter biological transcript but we consider the long transcript to be biologically relevant which means this will cause a truncated/absent protein. RS: The variant occurs in the penultimate exon of the shorter transcript, but is not alternatively spliced, and therefore is predicted to lead to a truncated protein.
PM2
Variant present in 1/111250 (0.0009%) European (non-Finnish) alleles in gnomAD. RS: Under current guidelines, this would reach PM2_Moderate (</= 0.007%)
PP4
Several Usher patients meeting this phenotypic requirement for USH2A

PM3_Very Strong
This can be upgraded to PM3_VS as there are several instances of this being observed in a homozygous state as well as a compound heterozygous state with variants such as the C759F variant which is a LP/P variant.

Not Met criteria codes
BP7
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP5
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP2
PM6
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM5
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS4
not used for AR

PS2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BA1
Variant present in 1/111250 (0.0009%) European (non-Finnish) alleles in gnomAD. RS: Under current guidelines, this would reach PM2_Moderate (</= 0.007%)
PP3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS1
Variant present in 1/111250 (0.0009%) European (non-Finnish) alleles in gnomAD. RS: Under current guidelines, this would reach PM2_Moderate (</= 0.007%)
BS4
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.